Cargando…

Intestinal neuropod cell GUCY2C regulates visceral pain

Visceral pain (VP) is a global problem with complex etiologies and limited therapeutic options. Guanylyl cyclase C (GUCY2C), an intestinal receptor producing cyclic GMP(cGMP), which regulates luminal fluid secretion, has emerged as a therapeutic target for VP. Indeed, FDA-approved GUCY2C agonists am...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barton, Joshua R., Londregan, Annie K., Alexander, Tyler D., Entezari, Ariana A., Bar-Ad, Shely, Cheng, Lan, Lepore, Angelo C., Snook, Adam E., Covarrubias, Manuel, Waldman, Scott A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9927949/ https://www.ncbi.nlm.nih.gov/pubmed/36548082 http://dx.doi.org/10.1172/JCI165578

Ejemplares similares

Silencing the intestinal GUCY2C tumor suppressor axis requires APC loss of heterozygosity
por: Pattison, Amanda M., et al.
Publicado: (2020)

Neuropods
por: Liddle, Rodger A.
Publicado: (2019)

Enteroendocrine cell regulation of the gut-brain axis
por: Barton, Joshua R., et al.
Publicado: (2023)

GUCY2C maintains intestinal LGR5(+) stem cells by opposing ER stress
por: Kraft, Crystal L., et al.
Publicado: (2017)

GUCY2C at the intersection of obesity and colorectal cancer
por: Waldman, Scott A, et al.
Publicado: (2013)

APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis
por: Blomain, Erik S., et al.
Publicado: (2020)

A β-Catenin-TCF-Sensitive Locus Control Region Mediates GUCY2C Ligand Loss in Colorectal Cancer
por: Rappaport, Jeffrey A., et al.
Publicado: (2021)

GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults
por: Cheslow, Lara, et al.
Publicado: (2023)

GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer
por: Marszalowicz, Glen P., et al.
Publicado: (2014)

GUCY2C Opposes Systemic Genotoxic Tumorigenesis by Regulating AKT-Dependent Intestinal Barrier Integrity
por: Lin, Jieru Egeria, et al.
Publicado: (2012)

Hormone suppression silencing GUCY2C is required for colorectal cancer
por: Waldman, Scott A
Publicado: (2015)

GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
por: Magee, Michael S., et al.
Publicado: (2016)

GUCY2C-targeted chimeric antigen receptor expressing T cells extend survival in a therapeutic mouse model of metastatic colorectal cancer
por: Magee, Michael S, et al.
Publicado: (2013)

Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity
por: Flickinger Jr, John C, et al.
Publicado: (2020)

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients
por: Snook, Adam E., et al.
Publicado: (2019)

A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients
por: Snook, Adam, et al.
Publicado: (2015)

Prolonged intestinal transit and diarrhea in patients with an activating GUCY2C mutation
por: von Volkmann, Hilde L., et al.
Publicado: (2017)

Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
por: Rampuria, Pragya, et al.
Publicado: (2023)

Congenital secretory diarrhoea caused by activating germline mutations in GUCY2C
por: Müller, Thomas, et al.
Publicado: (2016)

SELL and GUCY1A1 Gene Polymorphisms in Patients with Unstable Angina
por: Malinowski, Damian, et al.
Publicado: (2022)

Functional evaluation of GUCY1A3 mutations associated with myocardial infarction risk
por: Wobst, Jana, et al.
Publicado: (2015)

Overexpression of GUCY1A2 Correlates With Poor Prognosis in Gastric Cancer Patients
por: Li, Xin, et al.
Publicado: (2021)

A novel GUCY2D mutation in a Chinese family with dominant cone dystrophy
por: Zhao, Xin, et al.
Publicado: (2013)

Novel GUCY2D Gene Mutations in Japanese Male Twins with Leber Congenital Amaurosis
por: Hosono, Katsuhiro, et al.
Publicado: (2015)

A Potential Treatment of Congenital Sodium Diarrhea in Patients With Activating GUCY2C Mutations
por: van Vugt, Anke H.M., et al.
Publicado: (2021)

Preclinical studies in support of phase I/II clinical trials to treat GUCY2D-associated Leber congenital amaurosis
por: Boye, Sanford L., et al.
Publicado: (2022)

Postretinal Structure and Function in Severe Congenital Photoreceptor Blindness Caused by Mutations in the GUCY2D Gene
por: Aguirre, Geoffrey K., et al.
Publicado: (2017)

A natural history study of autosomal dominant GUCY2D-associated cone–rod dystrophy
por: Scopelliti, Amanda J., et al.
Publicado: (2023)

Functional study of two biochemically unusual mutations in GUCY2D Leber congenital amaurosis expressed via adenoassociated virus vector in mouse retinas
por: Boye, Sanford L., et al.
Publicado: (2016)

Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C
por: Mishra, Vishwas, et al.
Publicado: (2021)

Novel GUCY2C variant causing familial diarrhea in a Mennonite kindred and a potential therapeutic approach
por: Wolfe, Rachel M., et al.
Publicado: (2021)

A recurrent mutation in GUCY2D associated with autosomal dominant cone dystrophy in a Chinese family
por: Xiao, Xueshan, et al.
Publicado: (2011)

Novel GUCY2D mutation causes phenotypic variability of Leber congenital amaurosis in a large kindred
por: Gradstein, Libe, et al.
Publicado: (2016)

The pathogenicity of novel GUCY2D mutations in Leber congenital amaurosis 1 assessed by HPLC-MS/MS
por: Feng, Xue, et al.
Publicado: (2020)

Leber Congenital Amaurosis Due to GUCY2D Mutations: Longitudinal Analysis of Retinal Structure and Visual Function
por: Jacobson, Samuel G., et al.
Publicado: (2021)

RNF213 and GUCY1A3 in Moyamoya Disease: Key Regulators of Metabolism, Inflammation, and Vascular Stability
por: Mineharu, Yohei, et al.
Publicado: (2021)

Safety and improved efficacy signals following gene therapy in childhood blindness caused by GUCY2D mutations
por: Jacobson, Samuel G., et al.
Publicado: (2021)

Correction: Gut-associated cGMP mediates colitis and dysbiosis in a mouse model of an activating mutation in GUCY2C
por: Mishra, Vishwas, et al.
Publicado: (2021)

Gucy2d selectively marks inhibitory dynorphin neurons in the spinal dorsal horn but is dispensable for pain and itch sensitivity
por: Serafin, Elizabeth K., et al.
Publicado: (2021)

Clinical and Genetic Characteristics of 15 Affected Patients From 12 Japanese Families with GUCY2D-Associated Retinal Disorder
por: Liu, Xiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p0783826geuf93vnv2guqjnrjm